Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Regeneron Pharmaceuticals, Inc. (REGN) had Revenue of $3.03B for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$3.03B
Net Income	$808.70M
Cost of Goods Sold	$464.30M
Gross Profit	$2.56B
Operating Expenses	$2.44B
Operating Income	$591.70M
Non-Operating Income/Expense	$313.30M
Pre-Tax Income	$905.00M
Normalized Pre-Tax Income	$905.00M
Income after Taxes	$808.70M
Income from Continuous Operations	$808.70M
Consolidated Net Income/Loss	$808.70M
Normalized Income after Taxes	$808.70M
EBIT	$591.70M
EBITDA	$718.60M
Weighted-Average Shares Outstanding (Basic)	106.70M
Weighted-Average Shares Outstanding (Diluted)	111.20M
Earnings per Share (EPS) (Basic)	$7.58
Earnings per Share (EPS) (Diluted)	$7.27
Balance Sheet Financials
Current Assets	$17.57B
Property, Plant, and Equipment	$4.69B
Long-Term Assets	$19.97B
Total Assets	$37.55B
Current Liabilities	$3.57B
Long-Term Debt	$2.70B
Long-Term Liabilities	$4.59B
Total Liabilities	$8.16B
Common Equity	$29.39B
Tangible Shareholders Equity	$28.22B
Shareholders Equity	$29.39B
Common Shares Outstanding	108.20M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.05B
Cash Flow from Investing Activities	$647.50M
Cash Flow from Financial Activities	$-1.09B
Beginning Cash	$2.49B
End Cash	$3.09B
Increase/Decrease in Cash	$604.00M
Stock-Based Compensation	$255.70M
Common Stock Dividends Paid	$-93.80M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.93
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.08
Debt to Equity Ratio	0.09
Gross Margin	84.67%
Operating Margin	19.54%
EBIT Margin	19.54%
EBITDA Margin	--
Pre-Tax Profit Margin	29.88%
Profit Margin	26.70%
Free Cash Flow	$815.80M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.15
Receiveable Turnover	0.54
Days Sales in Receivables	165.25
Return on Equity	2.75%
Return on Tangible Equity	2.87%
Return on Assets	2.15%
Return on Investments	2.52%
Book Value Per Share	$271.60
Free Cash Flow per Share	$7.34
Operating Cash Flow per Share	$9.40

Data from Zacks Investment Research, Inc.